XTL Biopharmaceuticals Ltd (XTLB) stock
XTLBNasdaqPharmaceutical Preparations
$1.64−0.02 (-1.20%)
Close on Nov 12, 2026Market cap $15.52MP/E –Yield –
XTL Biopharmaceuticals EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -$0.01. The highest annual figure on record is $0.01 in fiscal 2018.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$0.01 | – |
| FY2024 | Dec 31, 2024 | -$0.00 | – |
| FY2023 | Dec 31, 2023 | -$0.00 | – |
| FY2022 | Dec 31, 2022 | -$0.00 | – |
| FY2021 | Dec 31, 2021 | $0.00 | – |
| FY2020 | Dec 31, 2020 | -$0.01 | – |
| FY2019 | Dec 31, 2019 | -$0.00 | -116.7% |
| FY2018 | Dec 31, 2018 | $0.01 | – |
| FY2017 | Dec 31, 2017 | -$0.00 | – |
| FY2016 | Dec 31, 2016 | -$0.01 | – |
| FY2015 | Dec 31, 2015 | -$0.02 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2022 | Jun 30, 2022 | -$0.00 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?